| 王 爽,郑秀艳,孙文华,陈俊华,毛奎艳.美沙拉嗪对溃疡性结肠炎患者血清CRP, IL-10及TNF-α水平的影响[J].,2017,17(14):2693-2696 |
| 美沙拉嗪对溃疡性结肠炎患者血清CRP, IL-10及TNF-α水平的影响 |
| Effect of Mesalazine on Serum Levels of CRP, IL-10 and TNF-α in Patients with Ulcerative Colitis |
| 投稿时间：2016-12-01 修订日期：2016-12-27 |
| DOI：10.13241/j.cnki.pmb.2017.14.022 |
| 中文关键词: 美沙拉嗪 溃疡性结肠炎 CRP IL-10 TNF-α |
| 英文关键词: Mesalazine Ulcerative colitis C-reactive protein Interleukin-10 Tumor necrosis factor alpha |
| 基金项目:辽宁省科技攻关计划项目(2011225038) |
|
| 摘要点击次数: 387 |
| 全文下载次数: 180 |
| 中文摘要: |
| 摘要 目的：探讨美沙拉嗪对溃疡性结肠炎患者血清CRP，IL-10及TNF-α水平的影响。方法：收集我院就诊的120例溃疡性结肠炎患者，随机分为实验组和对照组，每组60例。两组给予柳氮磺吡啶肠溶片治疗，实验组患者给予美沙拉嗪肠溶片治疗。观察并比较两组患者治疗前后血清C-反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）及白介素-10（IL-10）水平、临床疗效及安全性。结果：与治疗前相比，治疗后两组患者血清CRP及TNF-α水平均下降，而IL-10水平均升高，差异具有统计学意义（P<0.05）；与对照组相比，实验组患者血清CRP及TNF-α水平较低，而IL-10水平较高，差异具有统计学意义（P<0.05）；与对照组相比，实验组患者临床治疗有效率较高，不良反应发生率较低，差异具有统计学意义（P<0.05）。结论：美沙拉嗪能够抑制溃疡性结肠炎患者的炎症反应水平，降低CRP、TNF-α水平，升高IL-10水平，临床疗效较好，且用药安全。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of mesalazine on serum levels of CRP, IL-10 and TNF-α in of patients with ulcerative colitis. Methods: 120 patients with ulcerative colitis were randomly divided into the experimental group and the control group, with 60 cases in each group. The patients in the control group were treated with sulfasalazine enteric-coated tablets, while the patients in the experimental group were treated with mesalazine enteric-coated tablets. Then serum levels of C- reactive protein (CRP), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10), and clinical efficiency and safety in the two groups were observed and compared before and after the treatment. Results: Compared with before treatment, the serum levels of CRP and TNF-α decreased, while the levels of IL-10 increased in the two groups after treatment, and the differences were statistically significant (P<0.05); Compared with the control group, the serum levels of CRP and TNF-α were lower, and the IL-10 was higher in experimental group, and the differences were statistically significant (P<0.05); Compared with the control group, the clinical effective rate in the experimental group were higher, while the incidence of adverse reactions was lower, and the differences were statistically significant (P<0.05). Conclusion: Mesalazine can reduce the serum levels of IL-10, CRP and TNF-α in patients with ulcerative colitis, which is effective and safety for clinical treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
